← FDA DRUG APPROVALS

FDA ANDA · ANDA040750

SPIRONOLACTONE

Sponsor: OXFORD PHARMS

APPLICATION
ANDA040750
TYPE
ANDA
ORIGINAL APPROVAL
2006-08-29
LATEST ACTION
2023-06-23
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SPIRONOLACTONEPrescription
SPIRONOLACTONE 50MG · TABLET · ORAL
SPIRONOLACTONEPrescription
SPIRONOLACTONE 100MG · TABLET · ORAL
SPIRONOLACTONEPrescription
SPIRONOLACTONE 25MG · TABLET · ORAL

Approval history

2023-06-23Labeling · Supplement 29 · standardAP
2021-02-26Labeling · Supplement 26 · standardAP
2015-10-30Labeling · Supplement 17 · standardAP
2014-09-22Labeling · Supplement 7AP
2014-09-22Labeling · Supplement 15 · standardAP
2014-09-22Labeling · Supplement 12 · standardAP
2011-10-31Labeling · Supplement 3AP
2006-08-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →